University of Toledo Medical Center, Department of Internal Medicine, Toledo, OH 43614, USA.
Gradalis, Inc., Carrollton, Department of Medical Affairs, Carrollton, TX 75006, USA.
Future Oncol. 2021 Jul;17(21):2817-2830. doi: 10.2217/fon-2021-0072. Epub 2021 Jun 1.
Patients who have mutations of the genes or are at an increased risk for developing breast and ovarian cancer. function as tumor suppressor genes, responsible for regulating DNA repair, and play an essential role in homologous recombination. Mutation of results in homologous recombination deficiency and genomic instability which drives oncogenesis and cancer proliferation. Recently, gene expression has been implicated in regulating immune response. Here we discuss the signaling pathway of BRCA1/2 in relation to breast and ovarian cancer, with emphasis on how dysregulation facilitates the path to malignancy and current treatment options.
携带 或 基因突变的患者罹患乳腺癌和卵巢癌的风险增加。 作为肿瘤抑制基因发挥作用,负责调控 DNA 修复,在同源重组中发挥重要作用。 基因突变导致同源重组缺陷和基因组不稳定性,从而促进肿瘤发生和癌症增殖。最近, 基因表达被认为与免疫反应的调节有关。在这里,我们讨论了 BRCA1/2 基因在乳腺癌和卵巢癌中的信号通路,重点阐述了失调如何促进恶性转化的发生以及目前的治疗选择。